Today we’re thrilled to announce Mission Bio’s expansion into single-cell multi-omics, effectively doubling our market reach with industry-first capability for simultaneous genotype and phenotype out of single cells. With this launch, our Tapestri Platform is now the first and only platform capable of co-detecting key DNA variations (SNVs and CNVs) and protein expression from a single cell, enabling key insights to drive the development of more impactful, truly precise cancer therapies.
Over the past two decades, great strides have been made in the fight against cancer. Thanks to a more profound understanding of the disease, researchers began to develop treatments targeted at specific cellular mutations, rather than the earlier ‘spray-and-pray’ method of administering treatment.
But we’ve begun to see a plateau in the progress. Only 3% of cancer drugs tested in clinical trials between 2000 and 2015 have been approved to treat patients, and even those that have been approved are not as effective as we’d hope. What’s more, treatments aimed at specific biomarkers like DNA mutations aren’t effective in every patient with that mutation, resulting in high rates of relapse. Ultimately, many of the targets identified were singled-out using now-dated technologies and methods.
In short, not only are precision therapies currently limited — they’re not actually as precise as the name suggests. We’re looking to change that.
To better confront cancer and develop dynamic solutions that mirror the disease’s evolution, we require a more profound insight into every component that drives disease – that means tracking not just DNA mutations, but functional changes in protein. Simultaneously measuring genotype and phenotype gives us a view into the temporal dynamics of the cell, so for the first time we can get a precise understanding of how mutations lead to harmful proteins. With this insight, we can see the past, present, and future of each person’s cancer — determine how it evolves, and develop new therapeutic approaches aimed to prevent disease evolution and relapse.
As our first entry into this space, we’re pleased to partner with BioLegend to co-develop the first commercial solution for true multi-omics at the single-cell level. Biolegend is a market leader in providing protein antibodies to the research space, and we look forward to providing a joint solution to single-cell proteogenomic researchers..
Our friends from Saar Gill’s and Ross Levine’s Labs will present the findings of their work leveraging our technology on Wednesday, November 6th at AMP 2019 in Baltimore, Maryland. Our team will also be part of the exhibition at booth 2749.
At Mission Bio, we envision a world with a different relationship to complex diseases like cancer: a world where cancer is manageable, even curable. With these new capabilities, we’re on track to make that vision a reality.
